Meeting
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
Authors
Oliver Klein
Medical Oncology Unit, Austin Health, Heidelberg, Australia
Oliver Klein , Damien Kee , Adnan Nagrial , Ben Markman , Craig Underhill , Michael Michael , Caroline Lum , Andreas Behren , Jodie Palmer , Niall C. Tebbutt , Matteo S. Carlino , Jonathan S. Cebon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02923934
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4588)
DOI
10.1200/JCO.2020.38.15_suppl.4588
Abstract #
4588
Poster Bd #
196
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
First Author: Oliver Klein
Poster
2019 ASCO Annual Meeting
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
First Author: Oliver Klein
Poster
2018 ASCO Annual Meeting
A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2018 Gastrointestinal Cancers Symposium
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai